India’s pharmaceutical industry is on track to miss its ambitious 2030 sales target by a wide margin, with a government-backed trade body now projecting revenues of only $80 billion to $90 billion.
This revised outlook falls significantly short of the $130 billion goal set by the sector in April last year, reflecting a sharp deterioration in the external environment for Indian exporters.
The downgrade in expectations is driven by a confluence of trade policy uncertainty and logistical headwinds.
Persistent tariff threats from the United States, India’s largest export market for generic medicines, continue to weigh on investor sentiment and corporate planning.
Simultaneously, shipping disruptions in the Middle East are complicating supply chains and increasing transit costs, further eroding the sector’s growth trajectory.
The Strait of Hormuz remains a critical chokepoint for global energy and trade flows, with recent reports highlighting heightened risks for vessels transiting the region.